← Back to Search

Brachytherapy

HDR brachytherapy monotherapy for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by CSSS de Gatineau
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gleason Score 6 or 7
Biopsy proven Adenocarcinoma of the Prostate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 2 years and 5 years post treatment
Awards & highlights

Study Summary

This trial will test how effective and safe high-dose rate brachytherapy is for treating low- and intermediate-risk prostate cancer.

Who is the study for?
This trial is for men with prostate cancer that's not too advanced. Specifically, it's for those who've had a biopsy confirming Adenocarcinoma of the Prostate at an early stage (T1c, T2a or T2b), have a PSA level under 20 ng/ml, and a Gleason Score of 6 or 7.Check my eligibility
What is being tested?
The study is testing if High-dose rate (HDR) brachytherapy alone can be effective in treating low to intermediate risk prostate cancer. HDR brachytherapy involves placing high-energy radiation sources inside the prostate to kill cancer cells.See study design
What are the potential side effects?
Possible side effects from HDR brachytherapy may include discomfort during treatment, urinary issues like frequency or urgency, bowel changes, erectile dysfunction, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer has a Gleason score of 6 or 7.
Select...
My prostate cancer is confirmed by a biopsy.
Select...
My breast cancer is in an early stage, but not the smallest size.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 2 years and 5 years post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 2 years and 5 years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease-free survival
Secondary outcome measures
Genito-urinary (GU) toxicity
Other outcome measures
Gastro-Intestinal (GI) Toxicity
Overall survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: HDR brachytherapy monotherapyExperimental Treatment1 Intervention
Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.

Find a Location

Who is running the clinical trial?

CSSS de GatineauLead Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
Marc Gaudet 2014. "Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02077335.
All > Mens Health
~8 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top